Alzheimer's & Dementia·26 AugEstimating treatment effects in clinical studies of Alzheimer's disease: What are estimands and why do we need them?ReviewInterventionsPaper
AAIC 2025 Abstract·26 DecSequential Global Statistical Tests: A Novel Method for Evaluating Primary, Secondary and Exploratory Variables in a Hierarchy with an Accumulated Evidence ApproachComputational studyAI & dataPaper
AAIC 2025 Abstract·26 DecBreaking down the influences of placebo progression and percent slowing on the observed treatment difference in Alzheimer’s Disease clinical trials for populations in different disease stagesComputational studyBiomarkersPaper
AAIC 2025 Abstract·26 DecLeveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer's DiseaseComputational studyBiomarkersPaper
AAIC 2025 Abstract·25 DecReflection on Statistical Innovations in The Past 25 Years of Alzheimer’s Disease ResearchReviewIndustry & policyPaper
AAIC 2025 Abstract·25 DecSystematic review and meta‐analysis of Alzheimer’s disease clinical trial results over more than a quarter century (1994‐2025) ‐ overall evidence and time savingsReviewInterventionsPaper
AAIC 2025 Abstract·23 DecSpectris™ treatment is associated with significant time saved in the OVERTURE feasibility and open label extension (OLE) studyTrial in peopleInterventionsPaper